Erasca, Inc. Erasca, Inc.

Erasca, Inc.

ERAS

Rank in Stocks #3408
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Share Price
$14.75
Market Cap
$5.16B
Change (1 day)
8.30%
Change (1 year)
499.59%
Country
US
Trade Erasca, Inc. (ERAS)

Category

Healthcare
Number of shares outstanding for Erasca, Inc. (ERAS)
Number of shares outstanding as of June 2026: 311.34M
According to Erasca, Inc. latest financial reports and stock price the company's current number of shares outstanding is 311.34M. At the end of December 2023 the company had 150.18M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Erasca, Inc. (ERAS) from 2019 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 311.34M 33.15%
2024 233.82M 55.69%
2023 150.18M 23.08%
2022 122.02M 2.45%
2021 119.10M 0.12%
2020 118.96M 0.00%
2019 118.96M 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -18.45%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 27.19%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 53.82%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -80.03%
NL